Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the chipmaker's Vera Rubin architecture to support artificial intelligence use across its drug discovery and development operations. The pharmaceutical company said it will be the first life sciences group to acquire a DGX SuperPOD based on Vera Rubin.
Nvidia introduced the architecture earlier this year, which is designed for high-performance computing tasks such as data analysis and simulation. The DGX SuperPOD uses Nvidia's Tensor Cores, which are optimized for machine learning workloads, to enable faster and more accurate computations.
The acquisition will allow Bristol Myers Squibb to leverage Nvidia's AI technology across its drug discovery pipeline, enabling it to analyze large amounts of data more quickly and accurately. This move is seen as a significant step forward in the company's efforts to develop breakthrough cancer treatments using artificial intelligence.